FrancophonIA/ELRC3.0 huggingface dataset:
English: SVR12 for genotype 1-infected peginterferon+ribavirin-experienced subjects in SAPPHIRE-II
Spanish: RVS12 de los sujetos infectados por el genotipo 1, tratados previamente con Peginterferón y con Ribavirina, del ensayo SAPPHIRE-II
English: Mechanism: CYP3A4/Pgp inhibition by ketoconazole and paritaprevir/ ritonavir/ ombitasvir aprevir/ ritonavi r ombitasvir
Spanish: Mecanismo: inhibición de CYP3A4/P-gp por parte de ketoconazol y, paritaprevir/ ombitasvir/ritonavir dasabuvir + ombitasvir/ paritaprevir/ ritonavir
English: 0.5 mg single dose5
Spanish: 0,5 mg en una sola dosis5
English: If clinically indicated, higher doses of esomeprazole/lansopraz ole may be needed.
Spanish: Pueden utilzarse dosis más altas de esomeprazol/lansop razol cuando esté clínicamente indicado.
English: Dasabuvir and ombitasvir/paritaprevir/ritonavir in combination with ribavirin is recommended for 24 weeks in liver transplant recipients.
Spanish: Se recomienda el tratamiento de dasabuvir y ombitasvir/paritaprevir/ritonavir combinado con ribavirina durante 24 semanas en receptores de un trasplante hepático.
English: Arm A: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV
Spanish: Grupo A: dasabuvir y ombitasvir/paritaprevir/ritonavir + RBV
English: SVR12 for genotype 1b-infected treatment-naïve subjects in PEARL III
Spanish: RVS12 de los sujetos infectados por el genotipo 1b, naïve, del ensayo PEARL III
English: CYP3A4 inhibition by ritonavir.
Spanish: CYP3A4 por ritonavir.
English: HCV Genotype 1a dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV
Spanish: Genotipo 1a del VHC dasabuvir y ombitasvir/paritaprevir/ritonavir con RBV
English: buprenorphin e/ naloxone 4-24 mg/16 mg once daily8
Spanish: 4-24 mg/1-6 mg una vez al día8
English: Treated subjects (N=179) had a median age of 57 years (range: 26 to 70); 35.2% were prior pegIFN/RBV null responders; 28.5% were prior pegIFN/RBV partial responders; and 36.3% were prior pegIFN/RBV relapsers; 54.2% were male; 3.9% were Black; ; 12.8% had a history of depression or bipolar disorder; 87.7% had baseline HCV RNA levels of at least 800,000 IU/mL; 17.9% had portal fibrosis (F2) and 14.0% had bridging fibrosis (F3).
Spanish: Los sujetos tratados (n=179) tenían una mediana de edad de 57 años (intervalo: 26 a 70); 35,2 % eran sujetos con respuesta nula previa a pegIFN/RBV; 28,5 % eran sujetos con respuesta parcial previa a pegIFN/RBV; y 36,3 % eran sujetos con recidiva previa durante un régimen de pegIFN/RBV; 54,2 % eran varones; 3,9 % eran de raza negra; 12,8 % tenían antecedentes de depresión o trastorno bipolar; 87,7 % presentaban niveles basales de ARN del VHC de 800.000 UI/ml como mínimo; 17,9 % presentaban fibrosis portal (F2) y 14,0 % tenían fibrosis en puente (F3).
English: Arm B: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV (24 weeks)
Spanish: Grupo B: dasabuvir y ombitasvir/paritaprevir/ritonavir + RBV (24 semanas)
English: SVR12 for genotype 1a-infected treatment-naïve subjects in PEARL IV
Spanish: RVS12 de los sujetos infectados por el genotipo 1a, naïve, del ensayo PEARL IV
English: Treated subjects (N=631) had a median age of 52 years (range: 18 to 70); 54.5% were male; 5.4% were Black; 15.2% had a history of depression or bipolar disorder; 79.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 15.4% had portal fibrosis (F2) and 8.7% had bridging fibrosis (F3); 67.7% had HCV genotype 1a infection; 32.3% had HCV genotype 1b infection.
Spanish: Los sujetos tratados (n=631) tenían una mediana de edad de 52 años (intervalo: 18 a 70); 54,5 % eran varones; 5,4 % eran de raza negra; 15,2 % tenían antecedentes de depresión o trastorno bipolar; 79,1 % presentaban niveles basales de ARN del VHC de 800.000 UI/ml como mínimo; 15,4 % presentaban fibrosis portal (F2) y 8,7 % tenían fibrosis en puente (F3); 67,7 % tenían infección por el genotipo 1a del VHC; 32,3 % tenían infección por el genotipo 1b del VHC;
English: trimethopri m
Spanish: paritaprevi r
English: Very common
Spanish: Frecuentes
English: For a general comment on treatment of HIV co-infected patients, including a discussion on different antiretroviral regimens that may be used, please see section 4.4 (Treatment of HIV co-infected patients) and the Summary of Product Characteristics of ombitasvir/ paritaprevir /ritonavir.
Spanish: FÁRMACOS ANTIVIRALES CONTRA EL VIH: INHIBIDORES DE LA PROTEASA Ver sección 4.4 (Tratamiento de pacientes coinfectados con VIH) y la Ficha Técnica de ombitasvir/ paritaprevir/ritonavir para consultar la información general sobre el tratamiento de pacientes coinfectados con VIH, incluyendo información sobre los regímenes de tratamiento diferentes que pueden utilizarse.
English: Serum bilirubin elevations
Spanish: Niveles séricos elevados de bilirrubina
English: PEARL-IV - genotype 1a, treatment-naïve, without cirrhosis
Spanish: PEARL-IV - genotipo 1ª naïve al tratamiento, sin cirrosis.
English: PEARL-III - genotype 1b, treatment-naïve, without cirrhosis Design:
Spanish: PEARL-III - genotipo 1b, naïve al tratamiento, sin cirrosis.
English: Genotype 1a, without cirrhosis dasabuvir + ombitasvir/paritaprevir/ritonavir + ribavirin*
Spanish: Pacientes con genotipo 1a, sin cirrosis dasabuvir + ombitasvir/paritaprevir/ritonavir+ ribavirina*
English: Treated subjects (N=380) had a median age of 58 years (range: 21 to 71); 42.1% were treatment-naïve, 36.1% were prior pegIFN/RBV null responders; 8.2% were prior pegIFN/RBV partial responders, 13.7% were prior pegIFN/RBV relapsers; 70.3% were male; 3.2% were Black; 14.7% had platelet counts of less than 90 x 109/L; 49.7% had albumin less than 40 g/L; 86.1% had baseline HCV RNA levels of at least 800,000 IU/mL; 24.7% had a history of depression or bipolar disorder; 68.7% had HCV genotype 1a infection, 31.3% had HCV genotype 1b infection.
Spanish: Los sujetos tratados (n=380) tenían una mediana de edad de 58 años (intervalo: 21 a 71); 42,1 % eran sujetos naïve; 36,1 % tenían respuesta nula previa a pegIFN/RBV; 8,2 % tenían respuesta parcial previa a pegIFN/RBV; y 13,7 % eran sujetos con recidiva previa durante un régimen de pegIFN/RBV; 70,3 % eran varones; 3,2 % eran de raza negra; 14,7 % tenían recuentos de plaquetas inferiores a 90 x 109/l; 49,7 % tenían niveles de albúmina inferiores a 40 g/l; 86,1 % presentaban niveles basales de ARN del VHC de 800.000 UI/ml como mínimo; 24,7 % tenían antecedentes de depresión o trastorno bipolar; 68,7 % tenían infección por el VHC de genotipo 1a; y 31,3 % presentaban infección por el VHC de genotipo 1b.
English: If rosuvastatin treatment is required during the treatment period, the maximum daily dose of rosuvastatin should be 5 mg (see section 4.5, Table 2).
Spanish: Cabe esperar que dasabuvir con ombitasvir/paritaprevir/ritonavir incremente en más de 3 veces la exposición a rosuvastatina .Si se requiere el tratamiento con rosuvastatina durante el periodo de tratamiento, la dosis máxima diaria de rosuvastatina debe ser de 5 mg (ver sección 4.5, Tabla 2).
English: Co-administration of dasabuvir with medicinal products that are primarily metabolized by UGT1A1 result in increased plasma concentrations of such medicinal products; routine clinical monitoring is recommended for narrow therapeutic index medicinal products (i.e. levothyroxine).
Spanish: La administración conjunta de dasabuvir con medicamentos que son metabolizados de forma primaria por UGT1A1 conduce a un incremento de las concentraciones plasmáticas de estos medicamentos.
English: SVR12 for genotype 1b-infected peginterferon+ribavirin-experienced subjects in PEARL II
Spanish: RVS12 de los sujetos infectados por el genotipo 1b, tratados previamente con Peginterferón y con Ribavirina, del ensayo PEARL II
English: Cyclobenzap rine 5 mg single dose
Spanish: Ciclobenzaprina 5 mg una dosis dasabuvir + ombitasvir/
English: Genotype 1a, with compensated cirrhosis dasabuvir + ombitasvir/paritaprevir/ritonavir + ribavirin*
Spanish: Pacientes con genotipo 1a, con cirrosis compensada dasabuvir + ombitasvir/paritaprevir/ritonavir+ ribavirina*
English: OATP1B1/B 3 and
Spanish: OATP1B/BCRP por paritaprevir
English: Arm A: dasabuvir and ombitasvir/paritaprevir/ritonavir + RBV (12 weeks)
Spanish: Grupo A: dasabuvir y ombitasvir/paritaprevir/ritonavir + RBV (12 semanas)
English: ↑ norbu prenorphine
Spanish: ↓ ciclobenzaprina
English: In addition, M1 is a substrate of the hepatic uptake transporters OATP family and OCT1 and thus, the hepatocyte concentration and thereby contribution to efficacy, may be larger than dasabuvir.
Spanish: Y por tanto, la concentración en el hepatocito y por ello su eficacia, puede ser mayor que con dasavubir.
English: Emtricitabine/ tenofovir 200 mg once daily/300 mg once daily dasabu vir + ombitas vir/parit aprevir/ ritonavi r
Spanish: 200 mg una vez al día/300 mg una vez al día dasabuvir + ombitasvir/ paritaprevir/ ritonavir emtricitabina
English: global multicentre, open-label
Spanish: internacional multicéntrico, abierto.
English: Treatment outcome dasabuvir and ombitasvir/paritaprevir/ritonavir for 12 weeks With RBV
Spanish: Resultado del tratamiento dasabuvir + ombitasvir/paritaprevir/ritonavir durante 12 semanas Con RBV
English: AbbVie B.V. Tel: +31 (0)88 322 2843
Spanish: Tel: +31 (0)88 322 2843
English: dasabuvir and ombitasvir/paritaprevir /ritonavir + ribavirin
Spanish: dasabuvir y ombitasvir/paritaprevir/ ritonavir + ribavirina
English: For interactions with ombitasvir/ paritaprevir /ritonavir refer to the Summary of Product Characteristics.
Spanish: Para ver las interacciones con ombitasvir/paritaprevir/ritonavir, consultar su Ficha Técnica.
English: Adverse reactions identified with dasabuvir in combination with ombitasvir/paritaprevir/ritonavir or ombitasvir/paritaprevir/ritonavir and ribavirin
Spanish: Reacciones adversas identificadas con dasabuvir en combinación con ombitasvir/paritaprevir/ritonavir con o sin ribavirina.
English: Arm B: dasabuvir and ombitasvir/paritaprevir/ritonavir
Spanish: Grupo B: dasabuvir y ombitasvir/paritaprevir/ritonavir
English: No dose adjustment is necessary for emtricitabine/tenofovir and dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Spanish: No es necesario ajustar la dosis de emtricitabina/ tenofovir y dasabuvir + ombitasvir/ paritaprevir/ritonavir
English: Darunavir/ ritonavir 800/100 mg once daily (administere d in the evening)
Spanish: 800/100 mg una vez al día (administrados por la noche)
English: How to store Exviera
Spanish: Conservación de Exviera
English: Dose normalized sirolimus ratios are shown for interaction with ombitasvir/paritaprevir/ritonavir + dasabuvir.
Spanish: Ratios de dosis normalizados de sirolimus se muestran para la interacción con dasabuvir +ombitasvir/paritaprevir/ritonavir.
English: Mechanism: possibly due to UGT inhibition by paritaprevir, ombitasvir and dasabuvir.
Spanish: Mecanismo: posiblemente debido a inhibición de UGT por parte de paritaprevir, ombitasvir y dasabuvir.
English: България АбВи ЕООД
Spanish: АбВи ЕООД Тел.
English: HCV Genotype 1b dasabuvir and ombitasvir/paritaprevir/ritonavir
Spanish: Genotipo 1b del VHC dasabuvir y ombitasvir/paritaprevir/ritonavir
English: Uncommon: may affect up to 1 in 100 people
Spanish: Poco frecuentes: pueden afectar a más de 1 de cada 100 personas
English: Treated subjects (N=394) had a median age of 54 years (range: 19 to 71); 49.0% were prior pegIFN/RBV null responders; 21.8/% were prior pegIFN/RBV partial responders; and 29.2% were prior pegIFN/RBV relapsers; 57.6% were male; 8.1% were Black; 20.6% had a history of depression or bipolar disorder; 87.1% had baseline HCV RNA levels of at least 800,000 IU per mL; 17.8% had portal fibrosis (F2) and 14.5% had bridging fibrosis (F3); 58.4% had HCV genotype 1a infection; 41.4% had HCV genotype 1b infection.
Spanish: Los sujetos tratados (n=394) tenían una mediana de edad de 54 años (intervalo: 19 a 71); 49,0 % eran sujetos con respuesta nula previa a pegIFN/RBV; 21,8 % eran sujetos con respuesta parcial previa a pegIFN/RBV; y 29,2 % eran sujetos con recidiva previa durante un régimen de pegIFN/RBV; 57,6 % eran varones; 8,1 % eran de raza negra; 20,6 % tenían antecedentes de depresión o trastorno bipolar; 87,1 % presentaban niveles basales de ARN del VHC de 800.000 UI/ml como mínimo; 17,8 % presentaban fibrosis portal (F2) y 14,5 % tenían fibrosis en puente (F3); 58,4 % tenían infección por el genotipo 1a del VHC; 41,4 % tenían infección por el genotipo 1b del VHC.
English: GARNET - Genotype 1b, Treatment-Naïve without cirrhosis.
Spanish: GARNET-Genotipo 1b, naïve, sin cirrosis.
English: dasabuvir and ombitasvir/paritaprevir/ritonavir with weight-based ribavirin for 12 or 24 weeks
Spanish: Tratamiento: dasabuvir y ombitasvir/paritaprevir/ritonavir con ribavirina en función del peso corporal durante 12 ó 24 semanas.
English: Mechanism: increase in dasabuvir possibly due to CYP2C8 inhibition by trimethoprim ombitasvir
Spanish: Mecanismo: aumento de la exposición a dasabuvir debido a la inhibición de CYP2C8 y aumento de la exposición a paritaprevir posiblemente debido a la inhibición de OATP1B1 por parte de gemfibrozilo.
English: HIV ANTIVIRALS: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Rilpivirine2
Spanish: TRANSCRIPTASA INVERSA Rilpivirina2
English: No dose adjustment needed for dolutegravir when administered with dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Spanish: No se necesita ajuste de dosis de dolutegravir cuando se administra con dasabuvir + ombitasvir/paritaprevir/ritonavir.
English: • Feeling sick (nausea)
Spanish: • Sentirse enfermo (náuseas), estar enfermo (vómitos) o pérdida de apetito
English: ombitas vir/parit aprevir/r itonavir metformin
Spanish: ombitasvir/par itaprevir/ritona vir metformina
English: Tacrolimus 2 mg single dose7
Spanish: 2 mg en una sola dosis7
English: 400 mg twice daily
Spanish: 400/100 mg dos veces al día
English: randomised, global multicentre, open-label
Spanish: aleatorizado, multicéntrico global, abierto.
English: Angioedema General disorders and administration and administration site conditions
Spanish: Trastornos generales y alteraciones en el lugar de administración Muy frecuentes
English: IRON CHELATORS Deferasirox dasabu vir + ombitas vir/parit aprevir/ ritonavi r
Spanish: QUELANTES DEL HIERRO Deferasirox dasabuvir + ombitasvir/ paritaprevir/ ritonavir
English: nordiazepam
Spanish: ↓ nordiaze pam
English: Nevirapine etravirine dasabu vir + ombitas vir/parit aprevir/ ritonavi r
Spanish: Nevirapina etravirina dasabuvir + ombitasvir/ paritaprevir/ ritonavir
English: Mechanism: possibly due to UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir.
Spanish: Mecanismo: posiblemente debido a inhibición de UGT1A1 por parte de paritaprevir, ombitasvir y dasabuvir.
English: dasabuvir and ombitasvir/paritaprevir/ritonavir
Spanish: dasabuvir y ombitasvir/paritaprevir/ ritonavir
English: HIV ANTIVIRALS: PROTEASE INHIBITORS
Spanish: FÁRMACOS ANTIVIRALES CONTRA EL VIH: INHIBIDORES NO NUCLEÓSIDOS DE LA
English: Dasabuvir is administered with ombitasvir/paritaprevir/ritonavir.
Spanish: Dasabuvir se administra con ombitasvir/ paritaprevir /ritonavir.
English: Dasabuvir is administered with ombitasvir/ paritaprevir /ritonavir.
Spanish: Dasabuvir se administra con ombitasvir/paritaprevir/ritonavir.
English: ↓ dasabuvir ↓ paritaprevir ↓ ombitasvir
Spanish: ↔ dasabuvir ↔ ombitasvir
English: See section 4.2 for dosing recommendations in HCV/HIV-1 co-infected patients.
Spanish: Para consultar las recomendaciones posológicas en pacientes coinfectados VIH-1/VHC, ver la sección 4.2.
English: Mechanism: Unknown dasabu vir + ombitas vir/parit aprevir/ ritonavi r
Spanish: Mecanismo: desconocido dasabuvir + ombitasvir/ paritaprevir/ ritonavir
English: dasabu vir + ombitas vir/parit aprevir/ ritonavi r atazanavir
Spanish: dasabuvir + ombitasvir/ paritaprevir/ ritonavir atazanavir
English: Prior pegIFN/RBV null responder Prior pegIFN/RBV partial responder Prior pegIFN/RBV relapser Outcome for subjects without SVR12 On-treatment VF
Spanish: Naïve Tratados previamente con pegIFN + RBV Recidiva previa Respuesta parcial previa Respuesta nula previa
English: The pharmacokinetic properties of the combination of dasabuvir with ombitasvir/paritaprevir/ritonavir have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Table 18 shows mean Cmax and AUC of dasabuvir 250 mg twice daily with ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily following multiple doses with food in healthy volunteers.
Spanish: En la Tabla 18 se reflejan las medias de Cmáx y AUC alcanzadas después de administrar varias dosis de dasabuvir 250 mg dos veces al día y ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg una vez al día, acompañadas de alimentos, a voluntarios sanos.
English: While no change in the pharmacokinetics of warfarin is expected, close monitoring of INR is recommended with all vitamin K antagonists.
Spanish: Aunque no se prevee un cambio en la farmacocinética de warfarina, se recomienda una monitorización estrecha del índice internacional normalizado (INR) con todos los antagonistas de la vitamina K. Esto se debe a los cambios en la función hepática durante el tratamiento con dasabuvir + ombitasvir/ paritaprevir/ritonavir.
English: Other medicines and Exviera
Spanish: Toma de Exviera con otros medicamentos
English: NA No dose adjustment needed for abacavir or lamivudine when administered with dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Spanish: NA No se necesita ajuste de dosis de abacavir o lamivudina cuando se administra con dasabuvir + ombitasvir/paritaprevir/ritonavi
English: NA No dose adjustment needed for metformin when co-administered with dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Spanish: NA No se necesita ajuste de dosis de metformina cuando se administra de forma conjunta con dasabuvir + ombitasvir/paritaprev ir/ritonavir.
English: Rosuvastatin
Spanish: Rosuvastatina
English: No dose adjustment is necessary for methadone and dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Spanish: No es necesario ajustar la dosis de metadona y dasabuvir + ombitasvir/ paritaprevir/ritonavir
English: Mechanism: decrease possibly due to CYP1A2 induction by ritonavir dasabu vir +
Spanish: Mecanismo: disminución posiblemente debida a la inducción de CYP1A2 por ritonavir paritaprevir/ ritonavir dasabuvir ciclobenzaprina; incrementar la dosis si se indica clinicamente.
English: dasabu vir + ombitas vir/parit aprevir/ ritonavi r ciclosporin
Spanish: dasabuvir + ombitasvir/ paritaprevir/ ritonavir ciclosporina
English: Mechanism: OATP1B1 inhibition by paritaprevir.
Spanish: Pravastatina 10 mg una vez al día Mecanismo: inhibición de OATP1B1 por parte de paritaprevir.
English: For contra-indications with ombitasvir/ paritaprevir /ritonavir refer to the Summary of Product Characteristics.
Spanish: Para consultar las contraindicaciones con ombitasvir/paritaprevir/ritonavir ver su Ficha Técnica.
English: CYP3A/efflu x transporters by lopinavir and higher dose of ritonavir.
Spanish: Mecanismo: aumento de la exposición a paritaprevir, posiblemente debido a la inhibición de CYP3A o de los transportadores de eflujos por lopinavir y por la dosis más elevada de ritonavir.
English: 300 mg single dose itonavir ombitasvir/paritaprevir/ ritonavir.
Spanish: 300 mg una dosis dasabuvir + ombitasvir/ paritaprevir/ ritonavir paracetamol
English: dasabuvir and ombitasvir/paritaprevir/ritonavir with or without RBV for 12 or 24 weeks
Spanish: Diseño: multicéntrico, abierto Tratamiento: dasabuvir y ombitasvir/paritaprevir/ritonavir, con o sin RBV durante 12 o 24 semanas
English: 800/160 mg twice daily dasabu vir +
Spanish: 800/160 mg 2 veces al dia
English: ↔ es citalopram
Spanish: ANTIDEPRESIVOS Escitalopram
English: Do not take Exviera if any of the above apply to you.
Spanish: Si cumple alguna de las condiciones anteriores no tome Exviera.
English: dasabuvir and ombitasvir/paritaprevir /ritonavir
Spanish: dasabuvir + ombitasvir/ paritaprevir/ ritonavir
English: CYP3A by atazanavir and CYP3A inhibition by the additional dose of ritonavir.
Spanish: Mecanismo: aumento de la exposición a paritaprevir, posiblemente debido a la inhibición de OATP1B1/B3 y CYP3A por parte de atazanavir y a la inhibición de CYP3A por la dosis adicional de ritonavir.
English: dasabuvir and ombitasvir/paritaprevir/ritonavir with weight-based ribavirin for 12 weeks
Spanish: Tratamiento: dasabuvir y ombitasvir/paritaprevir/ritonavir con ribavirina en función del peso corporal durante 12 semanas.
English: MEDICINAL PRODUCTS USED IN MULTIPLE SCLEROSIS Teriflunomid e dasabu vir +
Spanish: FÁRMACOS UTILIZADOS EN LA ESCLEROSIS MÚLTIPLE Teriflunomida dasabuvir + ombitasvir/ paritaprevir/ ritonavir
English: Treatment outcome dasabuvir and ombitasvir/paritaprevir/ritonavir with RBV 12 weeks
Spanish: Resultado del tratamiento dasabuvir y ombitasvir/paritaprevir/ritonavir con RBV
English: NA No dose adjustment needed for sofosbuvir when administered with dasabuvir + ombitasvir/paritaprevir /ritonavir.
Spanish: NA No se necesita ajuste de dosis de sofosbuvir cuando se administra con dasabuvir+ombitasvi r/paritaprevir/ritonavir
English: Dose normalized cyclosporine ratios are shown for interaction with dasabuvir + ombitasvir/paritaprevir/ritonavir.
Spanish: Ratios de dosis normalizados de ciclosporina se muestran para la interacción con dasabuvir y ombitasvir/paritaprevir/ritonavir.
English: CYP3A4 inhibition by ritonavir and increase in paritaprevir exposures may be due to
Spanish: Mecanismo: el efecto sobre la ciclosporina se debe a la inhibición de CYP3A4 por parte de ritonavir y el aumento de la exposición a paritaprevir podría deberse a la inhibición de OATP/BCRP/P-gp por parte de ciclosporina.
English: dasabuvir and ombitasvir/paritaprevir/ritonavir without ribavirin for 12 weeks
Spanish: Tratamiento: dasabuvir y ombitasvir/paritaprevir/ritonavir sin ribavirirna durante 12 semanas.
English: Treatment outcome dasabuvir and ombitasvir/paritaprevir/ritonavir for 12 weeks
Spanish: Resultado del tratamiento dasabuvir y ombitasvir/paritaprevir/ritonavir durante 12 semanas
English: • Vomiting
Spanish: • Picor
English: Mechanism: P-gp inhibition by dasabuvir, paritaprevir, and ritonavir.
Spanish: Mecanismo: inhibición de P-gp intestinal por parte de paritaprevir y ritonavir dasabuvir + ombitasvir/ paritaprevir/ ritonavir
English: Treated subjects (N=305) had a median age of 54 years (range: 19 to 70); 65.2% were male; 11.8% were Black; 20.7% had a history of depression or bipolar disorder; 86.6% had baseline HCV RNA levels of at least 800,000 IU/mL; 18.4% had portal fibrosis (F2) and 17.7% had bridging fibrosis (F3).
Spanish: Los sujetos tratados (n=305) tenían una mediana de edad de 54 años (intervalo: 19 a 70); 65,2 % eran varones; 11,8 % eran de raza negra; 20,7 % tenían antecedentes de depresión o trastorno bipolar;
English: No dose adjustment is necessary for raltegravir or dasabuvir ombitasvir/paritaprevir/ ritonavir.
Spanish: No es necesario ajustar la dosis de raltegravir o dasabuvir + ombitasvir/ paritaprevir/ritonavir
English: Selected treatment emergent laboratory abnormalities
Spanish: Anomalías analíticas surgidas con el tratamiento seleccionado
English: Patients receiving ribavirin should also refer to the Summary of Product Characteristics of ribavirin.
Spanish: Si se administra de forma concomitante con ribavirina, consultar también la ficha técnica de ribavirina.
English: Mechanism: CYP3A4 induction by apalutamide, enzalutamide or mitotane.
Spanish: Mecanismo: inducción de CYP3A4 por parte de apalutamida, enzalutamida o mitotane dasabuvir + ombitasvir/ paritaprevir/ ritonavir
English: No dose adjustment needed for dasabuvir + ombitasvir/paritaprevir/ ritonavir.
Spanish: No se necesita ajuste de dosis para dasabuvir+ombitasvir /paritaprevir/ritonavir trimetoprim
English: Reduce pravastatin dose by 50%.
Spanish: NA Reducir la dosis de pravastatina en un
English: Mechanism: BCRP and Pgp inhibition by paritaprevir, ritonavir and dasabuvir dasabu vir +
Spanish: Mecanismo: inhibición de BCRP y P-gp por paritaprevir, ritonavir y dasabuvir dasabuvir + ombitasvir/ paritaprevir/ ritonavir sofosbuvir